Bionano Genomics financials
$1.73+2.98%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $6.7M | $8.0M | $7.4M | $6.7M | $6.5M | $8.2M | $6.1M | $7.8M | $8.8M | $10.7M | $9.3M |
| Gross profit | $4.3M | $3.3M | $3.4M | $3.4M | $3.5M | $2.9M | $3.4M | -$8.4M | $2.6M | $2.8M | $2.4M | $2.7M |
| Gross margin | 52.8% | 48.6% | 42.7% | 45.7% | 51.6% | 45.5% | 41.9% | −139.1% | 33.3% | 32.2% | 22.7% | 29.5% |
| Operating income | -$7.2M | -$7.9M | -$8.5M | -$8.5M | -$7.8M | -$8.5M | -$11.9M | -$43.9M | -$17.0M | -$31.1M | -$25.0M | -$113.2M |
| Net income | -$7.4M | -$8.3M | -$7.9M | -$8.5M | -$6.9M | -$3.1M | -$20.1M | -$44.2M | -$16.2M | -$31.4M | -$43.9M | -$112.6M |
| Net margin | −90.8% | −124.2% | −99.8% | −115.4% | −101.8% | −48.0% | −246.5% | −728.6% | −208.8% | −358.3% | −409.4% | −1208.0% |
| Diluted EPS | $-0.64 | $-0.76 | $-0.77 | $-1.59 | $-1.99 | $-1.15 | $-12.21 | $-30.92 | $-14.41 | $-35.75 | $-66.01 | $-193.20 |
| EBITDA | -$4.9M | -$5.6M | -$6.2M | -$6.2M | -$5.4M | -$6.0M | -$9.4M | -$17.0M | -$12.9M | -$23.0M | -$20.6M | -$32.3M |
| Operating cash flow | -$4.7M | -$5.7M | -$4.2M | -$5.9M | -$3.5M | -$2.8M | -$6.5M | -$13.3M | -$21.0M | -$28.1M | -$27.3M | -$28.8M |
| Free cash flow | -$4.7M | -$5.7M | -$4.2M | -$5.9M | -$3.5M | -$2.8M | -$6.5M | -$13.3M | -$21.1M | -$28.2M | -$28.0M | -$28.9M |
| Diluted shares | 11.5M | 11.0M | 10.3M | 5.3M | 3.4M | 2.7M | 1.6M | 1.4M | 1.1M | 0.9M | 0.7M | 0.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.7M | $3.4M | $3.0M | $3.1M | $3.6M | $3.6M |
| Short-term investments | $6.2M | $11.0M | $16.3M | $18.5M | $12.9M | $14.6M |
| Total debt | $3.7M | $3.7M | $13.7M | $13.6M | $15.5M | $3.8M |
| Total assets | $47.6M | $64.8M | $73.6M | $79.1M | $76.0M | $78.4M |
| Total liabilities | $16.0M | $27.3M | $29.2M | $29.3M | $30.6M | $30.2M |
| Shareholders' equity | $31.6M | $37.5M | $44.4M | $49.8M | $45.4M | $48.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology